{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:59Z","timestamp":1786980539385,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10147-023-02421-y","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T02:02:10Z","timestamp":1698112930000},"page":"1573-1584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-6258","authenticated-orcid":false,"given":"Takeshi","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihito","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-2816","authenticated-orcid":false,"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"issue":"11","key":"2421_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrurol.2017.125","volume":"14","author":"M Moschini","year":"2017","unstructured":"Moschini M, D\u2019Andrea D, Korn S et al (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14(11):651\u2013668. https:\/\/doi.org\/10.1038\/nrurol.2017.125","journal-title":"Nat Rev Urol"},{"issue":"1","key":"2421_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R et al (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Urol"},{"issue":"3","key":"2421_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","volume":"18","author":"TW Flaig","year":"2020","unstructured":"Flaig TW, Spiess PE, Agarwal N et al (2020) Bladder cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(3):329\u2013354. https:\/\/doi.org\/10.6004\/jnccn.2020.0011","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"2421_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383(13):1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"issue":"11","key":"2421_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"issue":"1","key":"2421_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033","journal-title":"Blood"},{"issue":"19","key":"2421_CR7","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1200\/jco.19.00538","volume":"37","author":"P Sharma","year":"2019","unstructured":"Sharma P, Siefker-Radtke A, de Braud F et al (2019) Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkmate 032 Nivolumab 1 mg\/kg plus Ipilimumab 3 mg\/kg expansion cohort results. J Clin Oncol 37(19):1608\u20131616. https:\/\/doi.org\/10.1200\/jco.19.00538","journal-title":"J Clin Oncol"},{"issue":"31","key":"2421_CR8","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/jco.20.01652","volume":"38","author":"AB Apolo","year":"2020","unstructured":"Apolo AB, Nadal R, Girardi DM et al (2020) Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J Clin Oncol 38(31):3672\u20133684. https:\/\/doi.org\/10.1200\/jco.20.01652","journal-title":"J Clin Oncol"},{"issue":"1","key":"2421_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L et al (2021) Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 14(1):156. https:\/\/doi.org\/10.1186\/s13045-021-01164-5","journal-title":"J Hematol Oncol"},{"key":"2421_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg0117","author":"J Wei","year":"2021","unstructured":"Wei J, Montalvo-Ortiz W, Yu L et al (2021) Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abg0117","journal-title":"Sci Immunol"},{"issue":"5","key":"2421_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203(5):1259\u20131271. https:\/\/doi.org\/10.1084\/jem.20052494","journal-title":"J Exp Med"},{"issue":"5","key":"2421_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M et al (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41(5):843\u2013852. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019","journal-title":"Immunity"},{"issue":"2","key":"2421_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.semradonc.2019.12.008","volume":"30","author":"JC Jagodinsky","year":"2020","unstructured":"Jagodinsky JC, Morris ZS (2020) Priming and propagating anti-tumor immunity: focal hypofractionated radiation for in situ vaccination and systemic targeted radionuclide theranostics for immunomodulation of tumor microenvironments. Semin Radiat Oncol 30(2):181\u2013186. https:\/\/doi.org\/10.1016\/j.semradonc.2019.12.008","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"2421_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/jco.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride S, Sherman E, Tsai CJ et al (2021) Randomized phase ii trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol 39(1):30\u201337. https:\/\/doi.org\/10.1200\/jco.20.00290","journal-title":"J Clin Oncol"},{"issue":"4","key":"2421_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A et al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22(4):450\u2013462. https:\/\/doi.org\/10.1016\/s1470-2045(20)30737-3","journal-title":"Lancet Oncol"},{"issue":"9","key":"2421_CR16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen W, Peulen HMU, Lalezari F et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5(9):1276\u20131282. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1478","journal-title":"JAMA Oncol"},{"issue":"305","key":"2421_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26(305):234\u2013241. https:\/\/doi.org\/10.1259\/0007-1285-26-305-234","journal-title":"Br J Radiol"},{"issue":"1","key":"2421_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/imr.12573","volume":"280","author":"N Brix","year":"2017","unstructured":"Brix N, Tiefenthaller A, Anders H et al (2017) Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev 280(1):249\u2013279. https:\/\/doi.org\/10.1111\/imr.12573","journal-title":"Immunol Rev"},{"issue":"2 Pt 1","key":"2421_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria S, Kawashima N, Yang AM et al (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11(2 Pt 1):728\u2013734","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2421_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.Cir-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park SS, Dong H, Liu X et al (2015) PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 3(6):610\u2013619. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0138","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2421_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1871520621666210608095512","volume":"22","author":"BM Sahoo","year":"2022","unstructured":"Sahoo BM, Banik BK, Borah P et al (2022) Reactive oxygen species (ROS): key components in cancer therapies. Anticancer Agents Med Chem 22(2):215\u2013222. https:\/\/doi.org\/10.2174\/1871520621666210608095512","journal-title":"Anticancer Agents Med Chem"},{"issue":"4","key":"2421_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.Cir-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM et al (2015) Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3(4):345\u2013355. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0196","journal-title":"Cancer Immunol Res"},{"issue":"18","key":"2421_CR23","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.Ccr-16-1673","volume":"23","author":"SJ Dovedi","year":"2017","unstructured":"Dovedi SJ, Cheadle EJ, Popple AL et al (2017) Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal t-cell populations when combined with PD-1 blockade. Clin Cancer Res 23(18):5514\u20135526. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1673","journal-title":"Clin Cancer Res"},{"issue":"7547","key":"2421_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547):373\u2013377. https:\/\/doi.org\/10.1038\/nature14292","journal-title":"Nature"},{"issue":"12","key":"2421_CR25","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","volume":"170","author":"M Chakraborty","year":"2003","unstructured":"Chakraborty M, Abrams SI, Camphausen K et al (2003) Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170(12):6338\u20136347. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6338","journal-title":"J Immunol"},{"issue":"3","key":"2421_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1269\/jrr.44.203","volume":"44","author":"M Kuwabara","year":"2003","unstructured":"Kuwabara M, Takahashi K, Inanami O (2003) Induction of apoptosis through the activation of SAPK\/JNK followed by the expression of death receptor Fas in X-irradiated cells. J Radiat Res 44(3):203\u2013209. https:\/\/doi.org\/10.1269\/jrr.44.203","journal-title":"J Radiat Res"},{"issue":"3","key":"2421_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/jrr\/rrv007","volume":"56","author":"Y Yoshimoto","year":"2015","unstructured":"Yoshimoto Y, Oike T, Okonogi N et al (2015) Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation. J Radiat Res 56(3):509\u2013514. https:\/\/doi.org\/10.1093\/jrr\/rrv007","journal-title":"J Radiat Res"},{"issue":"12","key":"2421_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A et al (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 17(12):725\u2013741. https:\/\/doi.org\/10.1038\/s41571-020-0413-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2421_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ijc.28015","volume":"133","author":"DW Vermeer","year":"2013","unstructured":"Vermeer DW, Spanos WC, Vermeer PD et al (2013) Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer 133(1):120\u2013129. https:\/\/doi.org\/10.1002\/ijc.28015","journal-title":"Int J Cancer"},{"issue":"3\u20134","key":"2421_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/B:CANC.0000031769.14728.bc","volume":"23","author":"DR Spitz","year":"2004","unstructured":"Spitz DR, Azzam EI, Li JJ et al (2004) Metabolic oxidation\/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 23(3\u20134):311\u2013322. https:\/\/doi.org\/10.1023\/B:CANC.0000031769.14728.bc","journal-title":"Cancer Metastasis Rev"},{"issue":"7850","key":"2421_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-021-03269-w","volume":"591","author":"M Tigano","year":"2021","unstructured":"Tigano M, Vargas DC, Tremblay-Belzile S et al (2021) Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. Nature 591(7850):477\u2013481. https:\/\/doi.org\/10.1038\/s41586-021-03269-w","journal-title":"Nature"},{"issue":"7054","key":"2421_CR32","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","volume":"436","author":"S Gasser","year":"2005","unstructured":"Gasser S, Orsulic S, Brown EJ et al (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436(7054):1186\u20131190. https:\/\/doi.org\/10.1038\/nature03884","journal-title":"Nature"},{"issue":"4","key":"2421_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","volume":"3","author":"SG Ellsworth","year":"2018","unstructured":"Ellsworth SG (2018) Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiat Oncol 3(4):512\u2013519. https:\/\/doi.org\/10.1016\/j.adro.2018.08.014","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"2421_CR34","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T et al (2017) DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 8(1):1751. https:\/\/doi.org\/10.1038\/s41467-017-01883-9","journal-title":"Nat Commun"},{"key":"2421_CR35","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1038\/srep19740","volume":"6","author":"CT Wu","year":"2016","unstructured":"Wu CT, Chen WC, Chang YH et al (2016) The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep 6:19740. https:\/\/doi.org\/10.1038\/srep19740","journal-title":"Sci Rep"},{"issue":"4","key":"2421_CR36","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","volume":"81","author":"EL Kachikwu","year":"2011","unstructured":"Kachikwu EL, Iwamoto KS, Liao YP et al (2011) Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 81(4):1128\u20131135. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.034","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2421_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/jci67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124(2):687\u2013695. https:\/\/doi.org\/10.1172\/jci67313","journal-title":"J Clin Invest"},{"issue":"1","key":"2421_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12967-021-03112-w","volume":"19","author":"T Hellevik","year":"2021","unstructured":"Hellevik T, Berzaghi R, Lode K et al (2021) Immunobiology of cancer-associated fibroblasts in the context of radiotherapy. J Transl Med 19(1):437. https:\/\/doi.org\/10.1186\/s12967-021-03112-w","journal-title":"J Transl Med"},{"issue":"5","key":"2421_CR39","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s43018-023-00547-6","volume":"4","author":"L van Hooren","year":"2023","unstructured":"van Hooren L, Handgraaf SM, Kloosterman DJ et al (2023) CD103(+) regulatory T cells underlie resistance to radio-immunotherapy and impair CD8(+) T cell activation in glioblastoma. Nat Cancer 4(5):665\u2013681. https:\/\/doi.org\/10.1038\/s43018-023-00547-6","journal-title":"Nat Cancer"},{"issue":"1","key":"2421_CR40","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","volume":"8","author":"H Liang","year":"2017","unstructured":"Liang H, Deng L, Hou Y et al (2017) Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun 8(1):1736. https:\/\/doi.org\/10.1038\/s41467-017-01566-5","journal-title":"Nat Commun"},{"issue":"1","key":"2421_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/2326-6066.Cir-19-0305","volume":"9","author":"M De Martino","year":"2021","unstructured":"De Martino M, Daviaud C, Diamond JM et al (2021) Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in irradiated Breast Cancer. Cancer Immunol Res 9(1):89\u2013102. https:\/\/doi.org\/10.1158\/2326-6066.Cir-19-0305","journal-title":"Cancer Immunol Res"},{"issue":"72","key":"2421_CR42","doi-asserted-by":"publisher","first-page":"eabl9330","DOI":"10.1126\/sciimmunol.abl9330","volume":"7","author":"RC Hsieh","year":"2022","unstructured":"Hsieh RC, Krishnan S, Wu RC et al (2022) ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol 7(72):eabl9330. https:\/\/doi.org\/10.1126\/sciimmunol.abl9330","journal-title":"Sci Immunol"},{"issue":"1","key":"2421_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1535-7163.Mct-18-0986","volume":"19","author":"A Rompr\u00e9-Brodeur","year":"2020","unstructured":"Rompr\u00e9-Brodeur A, Shinde-Jadhav S, Ayoub M et al (2020) PD-1\/PD-L1 immune checkpoint inhibition with radiation in bladder cancer: in situ and abscopal effects. Mol Cancer Ther 19(1):211\u2013220. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-0986","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2421_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijrobp.2022.06.054","volume":"114","author":"Y Chiang","year":"2022","unstructured":"Chiang Y, Tsai YC, Wang CC et al (2022) Tumor-DERIVED C-C Motif ligand 2 induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment. Int J Radiat Oncol Biol Phys 114(2):321\u2013333. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2421_CR45","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41467-021-23086-z","volume":"12","author":"S Shinde-Jadhav","year":"2021","unstructured":"Shinde-Jadhav S, Mansure JJ, Rayes RF et al (2021) Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. Nat Commun 12(1):2776. https:\/\/doi.org\/10.1038\/s41467-021-23086-z","journal-title":"Nat Commun"},{"issue":"2","key":"2421_CR46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10147-022-02172-2","volume":"28","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Sato GE, Yoshimura M et al (2023) The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation. Int J Clin Oncol 28(2):201\u2013208. https:\/\/doi.org\/10.1007\/s10147-022-02172-2","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"2421_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Le TQ, Massarelli E et al (2018) Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 6(1):46. https:\/\/doi.org\/10.1186\/s40425-018-0361-7","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2421_CR48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","volume":"25","author":"H Sato","year":"2020","unstructured":"Sato H, Okonogi N, Nakano T (2020) Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol 25(5):801\u2013809. https:\/\/doi.org\/10.1007\/s10147-020-01666-1","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"2421_CR49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/s1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895\u2013903. https:\/\/doi.org\/10.1016\/s1470-2045(17)30380-7","journal-title":"Lancet Oncol"},{"issue":"24","key":"2421_CR50","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342\u20132350. https:\/\/doi.org\/10.1056\/NEJMoa1809697","journal-title":"N Engl J Med"},{"issue":"5","key":"2421_CR51","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl N, Vandekerkhove G, Decaestecker K et al (2019) Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol 75(5):707\u2013711. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.009","journal-title":"Eur Urol"},{"issue":"5","key":"2421_CR52","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","volume":"39","author":"M Daro-Faye","year":"2021","unstructured":"Daro-Faye M, Kassouf W, Souhami L et al (2021) Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World J Urol 39(5):1331\u20131343. https:\/\/doi.org\/10.1007\/s00345-020-03440-4","journal-title":"World J Urol"},{"issue":"22","key":"2421_CR53","doi-asserted-by":"publisher","first-page":"8355","DOI":"10.1002\/cam4.3445","volume":"9","author":"H Fukushima","year":"2020","unstructured":"Fukushima H, Kijima T, Fukuda S et al (2020) Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: a preliminary study. Cancer Med 9(22):8355\u20138363. https:\/\/doi.org\/10.1002\/cam4.3445","journal-title":"Cancer Med"},{"issue":"2","key":"2421_CR54","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/ijms22020535","volume":"22","author":"H Fukushima","year":"2021","unstructured":"Fukushima H, Yoshida S, Kijima T et al (2021) Combination of cisplatin and irradiation induces immunogenic cell death and potentiates postirradiation anti-PD-1 treatment efficacy in urothelial carcinoma. Int J Mol Sci 22(2):535. https:\/\/doi.org\/10.3390\/ijms22020535","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2421_CR55","doi-asserted-by":"publisher","first-page":"e003868","DOI":"10.1136\/jitc-2021-003868","volume":"10","author":"K Nishimura","year":"2022","unstructured":"Nishimura K, Nishio K, Hirosuna K et al (2022) Efficacy of pembrolizumab and comprehensive CD274\/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. J Immunother Cancer 10(1):e003868. https:\/\/doi.org\/10.1136\/jitc-2021-003868","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2421_CR56","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bju.15603","volume":"130","author":"D Makrakis","year":"2022","unstructured":"Makrakis D, Talukder R, Diamantopoulos LN et al (2022) Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int 130(5):592\u2013603. https:\/\/doi.org\/10.1111\/bju.15603","journal-title":"BJU Int"},{"issue":"5","key":"2421_CR57","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.21873\/anticanres.16373","volume":"43","author":"T Sano","year":"2023","unstructured":"Sano T, Aizawa R, Ito K et al (2023) Efficacy and tolerability of second-line pembrolizumab with radiation therapy in advanced urothelial carcinoma. Anticancer Res 43(5):2119\u20132126. https:\/\/doi.org\/10.21873\/anticanres.16373","journal-title":"Anticancer Res"},{"key":"2421_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2022.12.001","volume":"39","author":"K Nakamori","year":"2023","unstructured":"Nakamori K, Yamazaki S, Komura K et al (2023) Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival. Clin Transl Radiat Oncol 39:100558. https:\/\/doi.org\/10.1016\/j.ctro.2022.12.001","journal-title":"Clin Transl Radiat Oncol"},{"key":"2421_CR59","doi-asserted-by":"publisher","first-page":"1035884","DOI":"10.3389\/fonc.2022.1035884","volume":"12","author":"V Voronova","year":"2022","unstructured":"Voronova V, Vislobokova A, Mutig K et al (2022) Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance. Front Oncol 12:1035884. https:\/\/doi.org\/10.3389\/fonc.2022.1035884","journal-title":"Front Oncol"},{"key":"2421_CR60","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","volume":"3","author":"EB Golden","year":"2014","unstructured":"Golden EB, Frances D, Pellicciotta I et al (2014) Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3:e28518. https:\/\/doi.org\/10.4161\/onci.28518","journal-title":"Oncoimmunology"},{"issue":"4","key":"2421_CR61","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00262-021-03036-w","volume":"71","author":"I Eke","year":"2022","unstructured":"Eke I, Aryankalayil MJ, Bylicky MA et al (2022) Long-term expression changes of immune-related genes in prostate cancer after radiotherapy. Cancer Immunol Immunother 71(4):839\u2013850. https:\/\/doi.org\/10.1007\/s00262-021-03036-w","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2421_CR62","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"AA Lugade","year":"2005","unstructured":"Lugade AA, Moran JP, Gerber SA et al (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174(12):7516\u20137523. https:\/\/doi.org\/10.4049\/jimmunol.174.12.7516","journal-title":"J Immunol"},{"issue":"16","key":"2421_CR63","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.Ccr-14-2824","volume":"21","author":"A Filatenkov","year":"2015","unstructured":"Filatenkov A, Baker J, Mueller AM et al (2015) Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 21(16):3727\u20133739. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2824","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2421_CR64","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.Ccr-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15(17):5379\u20135388. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0265","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2421_CR65","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","volume":"83","author":"D Schaue","year":"2012","unstructured":"Schaue D, Ratikan JA, Iwamoto KS et al (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83(4):1306\u20131310. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.09.049","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2421_CR66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","volume":"7","author":"M Grapin","year":"2019","unstructured":"Grapin M, Richard C, Limagne E et al (2019) Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer 7(1):160. https:\/\/doi.org\/10.1186\/s40425-019-0634-9","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2421_CR67","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1395996","volume":"7","author":"M Morisada","year":"2018","unstructured":"Morisada M, Clavijo PE, Moore E et al (2018) PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology 7(3):e1395996. https:\/\/doi.org\/10.1080\/2162402x.2017.1395996","journal-title":"Oncoimmunology"},{"issue":"7","key":"2421_CR68","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.Can-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette BC, Liang H, Lee Y et al (2011) The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71(7):2488\u20132496. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-2820","journal-title":"Cancer Res"},{"key":"2421_CR69","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618. https:\/\/doi.org\/10.1038\/ncomms15618","journal-title":"Nat Commun"},{"issue":"Supplement 4","key":"2421_CR70","first-page":"e827","volume":"203","author":"CMG Tholomier","year":"2020","unstructured":"Tholomier CMG, Shinde-Jadhav S, Ayoub M et al (2020) Optimizing sequence of therapy and radiation delivery when combined with PD-L1 immunecheckpoint inhibition in bladder cancer. J Urol 203(Supplement 4):e827\u2013e828","journal-title":"J Urol"},{"issue":"5","key":"2421_CR71","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE et al (2013) Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24(5):589\u2013602. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.014","journal-title":"Cancer Cell"},{"key":"2421_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000537","author":"HB Barsoumian","year":"2020","unstructured":"Barsoumian HB, Ramapriyan R, Younes AI et al (2020) Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000537","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2421_CR73","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.Cd-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa de Olza M et al (2022) Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov 12(1):108\u2013133. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0003","journal-title":"Cancer Discov"},{"issue":"10","key":"2421_CR74","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925\u2013931. https:\/\/doi.org\/10.1056\/NEJMoa1112824","journal-title":"N Engl J Med"},{"issue":"6","key":"2421_CR75","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.Cir-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden EB, Demaria S, Schiff PB et al (2013) An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1(6):365\u2013372. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0115","journal-title":"Cancer Immunol Res"},{"key":"2421_CR76","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fonc.2018.00612","volume":"8","author":"ZS Buchwald","year":"2018","unstructured":"Buchwald ZS, Wynne J, Nasti TH et al (2018) Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing. Dose Fractionation Front Oncol 8:612. https:\/\/doi.org\/10.3389\/fonc.2018.00612","journal-title":"Dose Fractionation Front Oncol"},{"issue":"6","key":"2421_CR77","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8767","volume":"12","author":"SJ Wang","year":"2020","unstructured":"Wang SJ, Jhawar SR, Rivera-Nunez Z et al (2020) The association of radiation dose-fractionation and immunotherapy use with overall survival in metastatic melanoma patients. Cureus 12(6):e8767. https:\/\/doi.org\/10.7759\/cureus.8767","journal-title":"Cureus"},{"issue":"1","key":"2421_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","volume":"40","author":"Y Abuodeh","year":"2016","unstructured":"Abuodeh Y, Venkat P, Kim S (2016) Systematic review of case reports on the abscopal effect. Curr Probl Cancer 40(1):25\u201337. https:\/\/doi.org\/10.1016\/j.currproblcancer.2015.10.001","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"2421_CR79","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S et al (2021) Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med 27(1):152\u2013164. https:\/\/doi.org\/10.1038\/s41591-020-1131-x","journal-title":"Nat Med"},{"issue":"9","key":"2421_CR80","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","volume":"5","author":"JM Bauml","year":"2019","unstructured":"Bauml JM, Mick R, Ciunci C et al (2019) Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol 5(9):1283\u20131290. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1449","journal-title":"JAMA Oncol"},{"issue":"2","key":"2421_CR81","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","volume":"16","author":"ED Brooks","year":"2019","unstructured":"Brooks ED, Chang JY (2019) Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 16(2):123\u2013135. https:\/\/doi.org\/10.1038\/s41571-018-0119-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2421_CR82","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00262-022-03346-7","volume":"72","author":"J Friedhoff","year":"2023","unstructured":"Friedhoff J, Schneider F, Jurcic C et al (2023) BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study. Cancer Immunol Immunother 72(6):1603\u20131618. https:\/\/doi.org\/10.1007\/s00262-022-03346-7","journal-title":"Cancer Immunol Immunother"},{"key":"2421_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2014.00001","volume":"4","author":"T Hellevik","year":"2014","unstructured":"Hellevik T, Martinez-Zubiaurre I (2014) Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol 4:1. https:\/\/doi.org\/10.3389\/fonc.2014.00001","journal-title":"Front Oncol"},{"issue":"10","key":"2421_CR84","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2017.2222","volume":"153","author":"J Doyen","year":"2017","unstructured":"Doyen J, Picard A, Naghavi AO et al (2017) Clinical outcomes of metastatic melanoma treated with checkpoint inhibitors and multisite radiotherapy. JAMA Dermatol 153(10):1056\u20131059. https:\/\/doi.org\/10.1001\/jamadermatol.2017.2222","journal-title":"JAMA Dermatol"},{"key":"2421_CR85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-1-4614-5915-6_7","volume":"772","author":"RF Thompson","year":"2014","unstructured":"Thompson RF, Maity A (2014) Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. Adv Exp Med Biol 772:147\u2013165. https:\/\/doi.org\/10.1007\/978-1-4614-5915-6_7","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2421_CR86","doi-asserted-by":"publisher","first-page":"1832760","DOI":"10.1080\/2162402x.2020.1832760","volume":"9","author":"BGL Vanneste","year":"2020","unstructured":"Vanneste BGL, Van Limbergen EJ, Dubois L et al (2020) Immunotherapy as sensitizer for local radiotherapy. Oncoimmunology 9(1):1832760. https:\/\/doi.org\/10.1080\/2162402x.2020.1832760","journal-title":"Oncoimmunology"},{"issue":"6","key":"2421_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157164","volume":"11","author":"KH Young","year":"2016","unstructured":"Young KH, Baird JR, Savage T et al (2016) Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS ONE 11(6):e0157164. https:\/\/doi.org\/10.1371\/journal.pone.0157164","journal-title":"PLoS ONE"},{"issue":"16","key":"2421_CR88","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/0008-5472.Can-15-3451","volume":"76","author":"M Hettich","year":"2016","unstructured":"Hettich M, Lahoti J, Prasad S et al (2016) Checkpoint antibodies but not T cell-recruiting diabodies effectively synergize with TIL-inducing \u03b3-irradiation. Cancer Res 76(16):4673\u20134683. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-3451","journal-title":"Cancer Res"},{"key":"2421_CR89","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fimmu.2017.00231","volume":"8","author":"B Frey","year":"2017","unstructured":"Frey B, R\u00fcckert M, Weber J et al (2017) Hypofractionated irradiation has immune stimulatory potential and induces a timely restricted infiltration of immune cells in colon cancer tumors. Front Immunol 8:231. https:\/\/doi.org\/10.3389\/fimmu.2017.00231","journal-title":"Front Immunol"},{"issue":"19","key":"2421_CR90","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.Can-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G et al (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74(19):5458\u20135468. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-1258","journal-title":"Cancer Res"},{"issue":"19","key":"2421_CR91","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/cncr.30138","volume":"122","author":"JM Qian","year":"2016","unstructured":"Qian JM, Yu JB, Kluger HM et al (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122(19):3051\u20133058. https:\/\/doi.org\/10.1002\/cncr.30138","journal-title":"Cancer"},{"issue":"2","key":"2421_CR92","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","volume":"133","author":"KA Ahmed","year":"2017","unstructured":"Ahmed KA, Kim S, Arrington J et al (2017) Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol 133(2):331\u2013338. https:\/\/doi.org\/10.1007\/s11060-017-2437-5","journal-title":"J Neurooncol"},{"issue":"1","key":"2421_CR93","doi-asserted-by":"publisher","first-page":"2066609","DOI":"10.1080\/2162402x.2022.2066609","volume":"11","author":"JC Hassel","year":"2022","unstructured":"Hassel JC, Schank TE, Smetak H et al (2022) Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). Oncoimmunology 11(1):2066609. https:\/\/doi.org\/10.1080\/2162402x.2022.2066609","journal-title":"Oncoimmunology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02421-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T10:05:41Z","timestamp":1701338741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02421-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02421-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}